<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749851</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 15196</org_study_id>
    <secondary_id>U01HD087182</secondary_id>
    <nct_id>NCT02749851</nct_id>
  </id_info>
  <brief_title>Placenta Imaging Project</brief_title>
  <acronym>PIP</acronym>
  <official_title>Functional Imaging of Human Placenta by MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the application of newly generated magnetic resonance
      imaging (MRI) protocols for the assessment of placental perfusion in human subjects. The
      primary objective is to validate and establish the utility of placental MRI in pregnant
      women. The study will be entirely MRI-technology based with collection of placental tissue at
      the time of infant delivery for later correlative studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The placenta provides all the nutrition from a pregnant mother to a developing fetus. A
      placenta that functions normally is needed to ensure normal fetal growth and development.
      Unfortunately, the placenta is the least understood human organ even though it is involved in
      all pregnancy complications. The placenta is so poorly understood because our current methods
      to look at it during pregnancy, like ultrasound, do not provide enough information about
      placental growth and function.

      This study will help provide information about:

        -  How the placenta grows and develops during pregnancy

        -  How the placenta delivers nutrients, like oxygen to the developing fetus

        -  If placental function using new advanced imaging tools can predict pregnancy
           complications like fetal growth restriction, stillbirth, preeclampsia and preterm labor

      This study will explore how blood flow to the placenta affects placental growth, fetal
      growth, and oxygen delivery to the fetus. Blood flow to the placenta may determine how the
      placenta supports fetal growth and development. Having a way to measure placental function
      during pregnancy may provide a way to understand normal pregnancies but importantly also
      identify pregnancies at increased risk for pregnancy complications.

      Additionally we want to have an ancillary intrauterine growth restriction (IUGR) arm; the
      objective of this ancillary study is to test the sensitivity of the placental MRI protocol in
      women with confirmed cases of IUGR in the third trimester.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Placental perfusion (Units of measure: ml/min) measured at 3 time points across gestation.</measure>
    <time_frame>Change from 16, 24, and 32 weeks gestation</time_frame>
    <description>This will allow perfusion changes across pregnancy to be quantified in women from the three study groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal cutoff values of placental MRI for placenta mediated adverse outcomes using receiver operating characteristics (ROC)</measure>
    <time_frame>Change from 16, 24, and 32 weeks gestation</time_frame>
    <description>Determine the sensitivity and specificity of placental MRI at 16, 24, and 32 weeks gestation for identifying risk of adverse clinical outcome identified later in pregnancy. Optimal cutoff values of placental MRI for placenta mediated adverse outcomes using receiver operating characteristics (ROC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of placenta-mediated adverse pregnancy outcomes</measure>
    <time_frame>39 weeks gestation</time_frame>
    <description>A binary variable indication whether the placenta-mediated adverse pregnancy has observed within 39 weeks gestation
Composite of placenta-mediated adverse pregnancy outcomes defined as the presence of at least one of the following:
Fetal death (not due to genetic or infectious etiology),
Preeclampsia or gestational hypertension,
Small for gestational age fetus &lt; 5%,
Oligohydramnios (defined as amniotic fluid index (AFI) &lt; 5 cm) prompting delivery prior to 39 weeks gestation,
Abnormal fetal heart rate tracing prompting delivery prior to 39 weeks gestation,
Abnormal umbilical artery Doppler velocimetry prompting delivery prior to 39 weeks gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Placenta histologic outcomes</measure>
    <time_frame>39 weeks gestation</time_frame>
    <description>Composite of placental histologic outcomes defined as the presence of one of the following:
accelerated villous maturation
abnormal villous cytotrophoblast proliferation
microscopic infarctions
decidual vasculopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of preeclampsia using standard clinical criteria</measure>
    <time_frame>39 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age fetus at 3% and 5%</measure>
    <time_frame>39 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery prior to 37 weeks gestation.</measure>
    <time_frame>37 weeks gestation</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>High Risk Pregnancy</condition>
  <arm_group>
    <arm_group_label>Non-smokers</arm_group_label>
    <description>Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smokers</arm_group_label>
    <description>Pregnant women that identify as smokers will receive the MRI Imaging intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk/Non-Smokers</arm_group_label>
    <description>Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Confirmed IUGR</arm_group_label>
    <description>Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.</description>
    <arm_group_label>High risk/Non-Smokers</arm_group_label>
    <arm_group_label>Non-smokers</arm_group_label>
    <arm_group_label>Smokers</arm_group_label>
    <other_name>magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI - IUGR</intervention_name>
    <description>Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.</description>
    <arm_group_label>Confirmed IUGR</arm_group_label>
    <other_name>magnetic resonance imaging</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens to be included:

      Maternal blood (10ml) taken at each MRI visit and prior to delivery Maternal urine taken at
      each MRI visit and prior to delivery Placental tissue collected at the time of delivery.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women who plan to deliver at OHSU or University of Utah hospitals and live within the areas
        served by those medical facilities.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Pregnant women will be recruited based on inclusion criteria for 3 subject groups:

          1. Non-smokers with low risk for placental insufficiency

          2. Smokers

          3. Non-smokers who are at a high risk for adverse outcomes based on prior clinical
             history.

        Inclusion criteria: Pregnant women fulfilling inclusion criteria, and not meeting exclusion
        criteria, will be invited to participate in this study.

        Inclusion criteria for all groups:

          1. Maternal age over 18 years and able to give informed consent

          2. Pregnant patient, as defined by positive pregnancy test for elevated Î²-human chorionic
             gonadotropin (HCG) and certain menstrual history, or early ultrasound, identified
             prior to 14 weeks of gestation

        Inclusion criteria for low risk group:

          1. No history of a second or third trimester loss

          2. No history of fetal growth restriction

        Inclusion criteria for high risk group:

          1. History of pregnancy complicated by placental insufficiency in a previous singleton
             pregnancy (i.e. severe preeclampsia requiring preterm delivery, preterm delivery due
             to placenta insufficiency (eg. fetal growth restriction (FGR), oligohydramnios,
             abnormal umbilical artery Doppler's, abnormal antenatal testing), FGR &lt;10% delivered
             at term; stillbirth attributed to placental cause, regardless of gestational age

          2. Not currently a smoker

          3. Pregnancy at risk for placental insufficiency due to clinical concerns (eg. chronic
             hypertension)

          4. Spontaneous preterm birth &lt;34 weeks

        Exclusion criteria: These criteria will exclude women whose medications, personality traits
        or obstetric conditions could confound their ability to complete a 1 hour MRI scan.

          1. Individuals with intellectual disability or who are incarcerated

          2. Multiple gestation

          3. Major fetal anomalies known to be associated with abnormal growth (i.e. major
             congenital heart defect, gastroschisis)

          4. Current maternal history of alcohol or illicit drug use

          5. Current medical problems requiring chronic treatment:

               -  Cancer

               -  Active liver disease (acute hepatitis, chronic active hepatitis, persistently
                  abnormal liver enzymes)

               -  Chronic pulmonary disease including asthma requiring regular use of medication

          6. Prior history of claustrophobia

          7. Metal implants

          8. Increased aneuploidy risk based on ultrasound findings or genetic testing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Frias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Women's Health Research Unit Confidential Recruitment Line</last_name>
    <phone>503-494-8748</phone>
    <email>PIP@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Women's Health Research Unit Confidential Recruitment Line</last_name>
      <phone>503-494-8748</phone>
      <email>PIP@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Antonio E. Frias</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>growth restriction</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

